alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE ENCAD,
INC. DECEMBER 31, 1999 FORM 10-K AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                           3,953
<SECURITIES>                                         0
<RECEIVABLES>                                   30,546
<ALLOWANCES>                                         0
<INVENTORY>                                     11,992
<CURRENT-ASSETS>                                51,794
<PP&E>                                          28,709
<DEPRECIATION>                                (14,445)
<TOTAL-ASSETS>                                  68,479
<CURRENT-LIABILITIES>                           15,972
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            12
<OTHER-SE>                                      51,232
<TOTAL-LIABILITY-AND-EQUITY>                    68,479
<SALES>                                        117,712
<TOTAL-REVENUES>                               117,712
<CGS>                                           66,171
<TOTAL-COSTS>                                   66,171
<OTHER-EXPENSES>                                47,357
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 203
<INCOME-PRETAX>                                  3,981
<INCOME-TAX>                                       917
<INCOME-CONTINUING>                              3,064
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,064
<EPS-BASIC>                                       0.26
<EPS-DILUTED>                                     0.26


</TABLE>
Exhibit 10.18

 

AMENDMENT

TO

PHARMACY DISTRIBUTION AND SERVICES AGREEMENT

 

THIS AMENDMENT TO PHARMACY DISTRIBUTION AND SERVICES AGREEMENT (“Amendment”) is made effective June 1, 2016 (“Effective Date”) between: CELGENE CORPORATION, 86 Morris Avenue, Summit NJ 07901 (together with its subsidiaries and affiliates, hereinafter collectively “Celgene”) and Diplomat Pharmacy Inc dba Diplomat Specialty Pharmacy,  4100 South Saginaw Street, Flint, MI  48507 (hereinafter, “Pharmacy”).

 

WHEREAS, Celgene and Pharmacy are all of the parties to that certain Pharmacy Distribution and Services Agreement dated July 1, 2013 (the “PDSA”) and wish to amend the PDSA.

 

NOW, THEREFORE, in consideration of the mutual promises contained in this Amendment and other good and valuable consideration, the receipt and sufficiency of which is acknowledged, the parties hereby agree as follows:

 

1.                                      AMENDMENT.  The first sentence of Section 12.1 of the PDSA which reads “This Agreement shall become effective on the Effective Date and, unless earlier terminated in accordance with this Section 12, shall continue in effect for an initial term ending on June 30, 2016.” is hereby deleted and replaced with:

 

This Agreement shall be effective on the Effective Date and, unless terminated in accordance with Section 12, shall continue for a term ending on June 30, 2017.

 

2.                                      NO OTHER CHANGES.  Except as amended by Section 1 above, there are no other amendments to PDSA at this time, and the PDSA as previously amended remains is in full force and effect, valid in accordance with its terms.

 

IN WITNESS WHEREOF, the parties hereby execute and enter into this Amendment as of the Effective Date first written above.

 

THIS AMENDMENT MUST BE EXECUTED, RETURNED TO, AND RECEIVED BY, CELGENE BY 12:00 NOON EST, MONDAY, NOVEMBER 30, 2015 OTHERWISE CELGENE RESERVES THE RIGHT TO RE-EVALUATE THE TERMS OF THIS AMENDMENT, INCLUDING BUT NOT LIMITED TO DECLARING THIS AMENDMENT NULL AND VOID.

 

	
CELGENE   CORPORATION
    	
DIPLOMAT   PHARMACY INC
    
	
 
    	
DBA   DIPLOMAT SPECIALTY PHARMACY
    
	
 
    	
 
    
	
By:
    	
/s/   JAMES KILGALLON
    	
 
    	
By:
    	
/s/   RYAN RUZZICONI
    
	
Name:
    	
James   Kilgallon
    	
 
    	
Name:
    	
Ryan   Ruzziconi
    
	
Title:
    	
Sr.   Director, Pricing & Contracting
    	
 
    	
Title:
    	
VP & General Counsel
    
	
Date:
    	
10/19/2015
    	
 
    	
Date:
    	
9/29/15
<PAGE>

EXHIBIT 99.1  CERTIFICATION FOR ANNUAL REPORTS ON FORM 10-K

I, Wilson Wong, certify that:

1. I have reviewed this annual report on Form 10-K of Asante' Technologies, Inc.
("Registrant");

2 Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
Registrant as of, and for, the periods presented in this annual report;

4. The Registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the Registrant and we have:

     a) designed such disclosure controls and procedures to ensure that material
     information relating to the Registrant, including its consolidated
     subsidiaries, is made known to us by others within those entities,
     particularly during the period in which this annual report is being
     prepared;

     b) evaluated the effectiveness of the Registrant's disclosure controls and
     procedures as of a date within 90 days prior to the filing date of this
     annual report (the "Evaluation Date"); and

     c) presented in this annual report our conclusions about the effectiveness
     of the disclosure controls and procedures based on our evaluation as of the
     Evaluation Date;

5. The Registrant's other certifying officer and I have disclosed, based on our
most recent evaluation, to the Registrant's auditors and the audit committee of
Registrant's board of directors (or persons performing the equivalent function):

     a) all significant deficiencies in the design or operation of internal
     controls which could adversely affect the Registrant's ability to record,
     process, summarize and report financial data and have identified for the
     Registrant's auditors any material weaknesses in internal controls; and

     b) any fraud, whether or not material, that involves management or other
     employees who have a significant role in the Registrant's internal
     controls; and

6. The Registrant's other certifying officer and I have indicated in this annual
report whether or not there were significant changes in internal controls or in
other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date: January 9, 2002

                                            /s/ WILSON WONG
                                            ----------------------------------
                                            Wilson Wong, President and
                                            Chief ExecutiveOfficer
START TALKING BEFORE SHE HEADS OFF TO SCHOOL.

It’s never too early to have a conversation about alcohol and other drugs.

The sooner you talk about the dangers of underage drinking and substance use, the greater chance 

you have of influencing your child’s decisions about using alcohol and other drugs. For tips on how—

and when—to begin the conversation, visit 

www.underagedrinking.samhsa.gov

#TalkTheyHearYou PEP20-03-01-042
# C_2012303EN.01000501.xml

| 6.10.2012 | EN | Official Journal of the European Union | C 303/5 |
| --- | --- | --- | --- |

6.10.2012

EN

Official Journal of the European Union

C 303/5

---

Order of the Court (Third Chamber) of 12 July 2012 (reference for a preliminary ruling from the Tribunale ordinario di Brescia — Italy) — Gennaro Currà and Others v Bundesrepublik Deutschland

(Case C-466/11) (1)

1

(Reference for a preliminary ruling - Article 92(1) of the Rules of Procedure - Action brought by the victims of massacres against a Member State as the party liable for acts committed by its armed forces in wartime - Charter of Fundamental Rights of the European Union - Clear lack of jurisdiction of the Court)

2012/C 303/08

Language of the case: Italian

Referring court

Referring court

Tribunale ordinario di Brescia

Parties to the main proceedings

Parties to the main proceedings

Applicants: Gennaro Currà, Nadia Orlandi heir of Aldo Orlandi, Renzo Ciro Malago heir of Federico Malago, Ruberto Ezecchia, Camillo Turchetti, Franco Forni, Ilva Morselli heir of Ermenegildo Morselli, Elisa Ghisolfi and Anna Ghisolfi joint heirs of Luca Ghisolfi, Primo Zelioli, Francesco Perondi, Anna Furgeri heir of Agide Furgeri, Elena Penzani and Gian Luigi Penzani joint heirs of Carlo Penzani, Renato Mortari, Ada Zaccaria heir of Sigifredo Zaccaria, Erino Alberti, Gabriella Boccaletti heir of Mario Boccaletti, Rita Boccasanta heir of Ernesto Boccasanta, Alberto Borelli, Pierantonio Foresti heir of Franco Foresti, Irmo Sancassiani, Ennio Mischi heir of Aldo Mischi, Graziano Broglia heir of Rosolino Broglia, Alba Spinella and Maria Raffaella Spinella joint heirs of Vincenzo Rocco Spinella, Giuseppe Ferri, Alessandra Fontanabona heir of Giulio Fontanabona, Luciana, Mariuccia and Giulietta Pedratti joint heirs of Carlo Pedratti, Raffaele Colucci

Applicants:

Defendant: Bundesrepublik Deutschland

Defendant:

In the presence of: Repubblica italiana

In the presence of:

Re:

Re:

Reference for a preliminary ruling — Tribunale ordinario di Brescia — Interpretation of Articles 3, 4(3), 6 and 21 TEU and Articles 17, 47 and 52 of the Charter of Fundamental Rights of the European Union — Crimes against humanity — Action brought by victims of massacres against a Member State as the party liable for acts committed by its armed forces in wartime — Victims’ right to compensation — Whether time-barring of this right is permissible — Whether it is permissible that the Member State in question should claim immunity from jurisdiction

Operative part of the order

Operative part of the order

It is clear that the Court of Justice of the European Union has no jurisdiction to take cognisance of the request for a preliminary ruling submitted by the Tribunale ordinario di Brescia (Italy).

---

(1)  OJ C 347, 26.11.2011.

1

---
Editorial Note on Part 260
Editorial Note: For Federal Register citations affecting forms listed in part 260, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at *www.govinfo.gov .*

§ 260.2 FERC Form No. 2-A, Annual report for Nonmajor natural gas companies. ( a ) *Prescription.* The form of Annual Report for Nonmajor Natural Gas Companies, designated herein as FERC Form No. 2—A, is prescribed.
( b ) *Filing requirements.* Each natural gas company, as defined by the Natural Gas Act, not meeting the filing threshold for FERC Form No. 2, but having total gas sales or volume transactions exceeding 200,000 Dth in each of the three previous calendar years, must prepare and file with the Commission, as follows: ( 1 ) The annual report for the year ending December 2004 must be filed on April 25, 2005.
( 2 ) The annual report for each year thereafter must be filed on April 18 of the subsequent year.
( 3 ) Newly established entities must use projected data to determine whether FERC Form No. 2-A must be filed.
( 4 ) The form must be filed in electronic format only, as indicated in the General Instructions set out in that form. The format for the electronic filing is available through the Commission's website, *https://www.ferc.gov .* One copy of the report must be retained by the respondent in its files.
(Natural Gas Act, as amended, 15 U.S.C. 717-717w; Natural Gas Policy Act of 1978, 15 U.S.C. 3301-3432; Federal Power Act, as amended, 16 U.S.C. 792-828c; Department of Energy Organization Act, 42 U.S.C. 7101-7352; E.O. 12009, 3 CFR part 142 (1978))
[Order 101, 45 FR 60900, Sept. 15, 1980, as amended by Order 390, 49 FR 32527, Aug. 14, 1984; Order 493, 53 FR 15031, Apr. 27, 1988; Order 581, 60 FR 53071, Oct. 11, 1995; Order 628, 68 FR 269, Jan. 3, 2003; 69 FR 9044, Feb. 26, 2004; Order 899, 88 FR 74031, Oct. 30, 2023]
<PAGE>

                                                                EXHIBIT 10.47



Nutrition For Life International, Inc.
9101 Jameel
Houston, Texas 77040

Dear Gentlemen and Ladies:

This letter agreement is being provided in connection with a merger transaction
in which I will be receiving shares of convertible preferred stock of Nutrition
For Life International, Inc. (the "Company").  I understand that a condition to
closing of the merger is the execution and delivery to the Company of this
lockup agreement.

For a period of one year from the date of closing of the merger, I will not,
directly or indirectly, sell, offer to sell, contract to sell (including without
limitation, any short sale), grant any option to purchase or otherwise transfer
or dispose of (other than to parents, siblings, spouses or lineal descendants or
a trust for any of the foregoing who agree to these restrictions) any of the
securities received by me from the Company in connection with the merger
(including any securities which are received upon conversion of the convertible
preferred stock).

I acknowledge and agree that (a) I will be benefited directly and indirectly by
an investment in the Company and by the merger and the Company's officers,
directors and shareholders may rely on the agreement set forth in this letter
and (b) this letter agreement may be specifically enforced because of the
irreparable harm that could result from any breaches of this letter agreement.
This letter agreement shall be governed by and construed in accordance with the
laws of the State of Texas.  In the event any one or more provisions of this
letter agreement should be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any
other provisions hereof.

Dated: November 17, 1999                          ______________________________
                                                  Signature

                                                  Barry C. Loder
                                                  ------------------------------
                                                  Print Name
<PAGE>   1


                                                                      EXHIBIT 15




                    ACKNOWLEDGMENT OF INDEPENDENT ACCOUNTANTS


Board of Directors
The MIIX Group, Incorporated

We are aware of the incorporation by reference in the Registration Statement
(Form S-8) of the MIIX Group, Incorporated, pertaining to the 1998 Long Term
Incentive Equity Plan of the MIIX Group, Incorporated, of our report dated May
5, 2000 relating to the unaudited consolidated interim financial statements of
the MIIX Group, Incorporated and subsidiaries included in this Form 10-Q filed
on May 15, 2000 for the quarter ended March 31, 2000.


                                         ERNST & YOUNG LLP


New York, New York
May 5, 2000
**Exhibit 32.2**

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1250,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of Power3 Medical Products, Inc.(the “Company”) on Form 10-QSB for the period ending March 31, 2005as filed with the Securities and Exchange Commission on the date hereof (the “Report”),I, John P. Burton,  Chief  Accounting Officer  of the  Company, certify,  to the  best of my knowledge,  pursuant to 18 U.S.C.  Section 1350, as adopted pursuant to Section 906of the Sarbanes-Oxley Act of 2002, that:

 

The Report fully compiles with the requirements of Section 13(a) or15(d) of the Securities Exchange Act of 1934; and

 

The information contained in the Report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.

 

 
| September 9, 2005 | /s/ John P. Burton                       |   |
|-------------------|------------------------------------------|--------|
|              |  John P. Burton                     |
|              |  Chief Accounting Officer           |
|              |  Power3 Medical Products, Inc. |

 

1

----
Exhibit 23.1  

CONSENT OF INDEPENDENT AUDITORS

 

THE BOARD OF DIRECTORSSOLECTRON CORPORATION:

We consent to the incorporation by reference in theregistration statements (Nos. 333-69443, 333-46304, 333-46300, 333-40176, 333-34494,333-92269, 333-75865, 333-85949, 333-89035, 333-75813, 333-24293, 333-02523, 333-17643,33-58580, 33-46686, 33-57575, 33-75270, 33-33461, 333-56220,333-56464, 333-60684, 333-64454 and 333-69182) on Forms S-3, S-4 and S-8 ofSolectron Corporation of our report dated September 17, 2001, relating to theconsolidated balance sheets of Solectron Corporation and subsidiaries as ofAugust 31, 2001 and 2000, and the related consolidated statements of operations,stockholders' equity, comprehensive income (loss) and cash flows for each of theyears in the three-year period ended August 31, 2001, and the related financialstatement schedule, which report appears in the August 31, 2001, annual reporton Form 10-K of Solectron Corporation.

 

 

KPMG LLP

 

Mountain View, CaliforniaNovember 13, 2001

----
#### The People of the State of New York, Respondent, v Wayne Norris, Appellant.

[823 NYS2d 691]

Application by the appellant for a writ of error coram nobis to vacate, on the ground of ineffective assistance of appellate counsel, a decision and order of this Court dated January 27, 2003 *(People v Norris,*301 AD2d 664 [2003]), modifying a judgment of the Supreme Court, Kings County, rendered April 18, 2000.

Ordered that the application is denied.

The appellant has failed to éstablish that he was denied the effective assistance of appellate counsel *(see Jones v Barnes,*463 US 745 [1983]; *People v Stultz,*2 NY3d 277 [2004]). Prudenti, P.J., Florio, Santucci and Goldstein, JJ., concur.
#### § 95.26 Blood meal, blood albumin, intestines, and other animal byproducts for industrial use; requirements for unrestricted entry.

Blood meal, blood albumin, bone meal, intestines, or other animal materials intended for use in the industrial arts shall not be imported except subject to handling and treatment in accordance with § 95.27, unless such products originated in and were shipped directly from a region not declared by the Secretary of Agriculture to be infected with foot-and-mouth disease.

(Approved by the Office of Management and Budget under control number 0579-0015)

[28 FR 5981, June 13, 1963, as amended at 59 FR 67134, Dec. 29, 1994; 62 FR 56024, Oct. 28, 1997. Redesignated and amended at 78 FR 73003, 73007, Dec. 4, 2013; 83 FR 15494, Apr. 11, 2018]
### §689p. Regulations

The Administrator may issue such regulations as it deems necessary to carry out the provisions of this part in accordance with its purposes.

(Pub. L. 85–699, title III, §367, as added Pub. L. 106–554, §1(a)(8) [§1(b)(3)], Dec. 21, 2000, 114 Stat. 2763, 2763A–664.)
#### Delphine Lameni, Appellant, v Verizon et al., Respondents, et al., Defendants.

[823 NYS2d 679]

In an action to recover *536damages for personal injuries, the plaintiff appeals (1) from an order of the Supreme Court, Kings County (Ambrosio, J.), dated November 15, 2004, which granted the motion of the defendants Verizon New York, Inc., sued herein as Verizon, Bell Atlantic, New York Telephone Company, and NYNEX, and Leanthony Meeks for summary judgment dismissing the complaint insofar as asserted against them on the ground that the plaintiff did not sustain a serious injury within the meaning of Insurance Law § 5102 (d) and (2), as limited by her brief, from so much of an order of the same court dated May 9, 2005, as, in effect, upon reargument, adhered to the original determination.

Ordered that the appeal from the order dated November 15, 2004 is dismissed, as that order was superseded by the order dated May 9, 2005, made upon reargument; and it is further,

Ordered that the order dated May 9, 2005 is reversed insofar as appealed from, on the law, upon reargument, the order dated November 15, 2004 is vacated, and the motion for summary judgment dismissing the complaint insofar as asserted against the respondents is denied; and it is further,

Ordered that one bill of costs is awarded to the plaintiff.

The respondents failed to establish a prima facie case that the plaintiff did not sustain a serious injury within the meaning of Insurance Law § 5102 (d) *(see Connors v Flaherty,*32 AD3d 891 [2006]). Accordingly, the Supreme Court should have denied their motion for summary judgment dismissing the complaint insofar as asserted against them. In light of the foregoing, we need not consider the sufficiency of the papers submitted in opposition *(see Mariaca-Olmos v Mizrhy,*226 AD2d 437, 438 [1996]). Crane, J.P., Krausman, Spolzino and Skelos, JJ., concur.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               MAR-31-1999
<CASH>                                          27,104
<SECURITIES>                                    81,698
<RECEIVABLES>                                   22,082
<ALLOWANCES>                                     9,497
<INVENTORY>                                        559
<CURRENT-ASSETS>                               142,545
<PP&E>                                          69,278
<DEPRECIATION>                                  28,130
<TOTAL-ASSETS>                                 194,557
<CURRENT-LIABILITIES>                           37,724
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            42
<OTHER-SE>                                     156,494
<TOTAL-LIABILITY-AND-EQUITY>                   194,557
<SALES>                                        149,886
<TOTAL-REVENUES>                               149,886
<CGS>                                           14,286
<TOTAL-COSTS>                                   14,286
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 27,394
<INCOME-TAX>                                     7,610
<INCOME-CONTINUING>                             19,784
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    19,784
<EPS-BASIC>                                     0.51
<EPS-DILUTED>                                     0.44


</TABLE>